CA2264780C - Methods and materials for optimization of electronic hybridization reactions - Google Patents
Methods and materials for optimization of electronic hybridization reactions Download PDFInfo
- Publication number
- CA2264780C CA2264780C CA002264780A CA2264780A CA2264780C CA 2264780 C CA2264780 C CA 2264780C CA 002264780 A CA002264780 A CA 002264780A CA 2264780 A CA2264780 A CA 2264780A CA 2264780 C CA2264780 C CA 2264780C
- Authority
- CA
- Canada
- Prior art keywords
- buffer
- histidine buffer
- histidine
- hybridization
- target nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000009396 hybridization Methods 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title claims description 63
- 238000006243 chemical reaction Methods 0.000 title abstract description 5
- 239000000463 material Substances 0.000 title description 2
- 238000005457 optimization Methods 0.000 title 1
- 239000000872 buffer Substances 0.000 claims abstract description 107
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims abstract description 78
- 235000018417 cysteine Nutrition 0.000 claims abstract description 29
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 29
- 238000012360 testing method Methods 0.000 claims abstract description 29
- 238000004377 microelectronic Methods 0.000 claims abstract description 11
- 108020004707 nucleic acids Proteins 0.000 claims description 38
- 150000007523 nucleic acids Chemical class 0.000 claims description 38
- 102000039446 nucleic acids Human genes 0.000 claims description 38
- 230000003139 buffering effect Effects 0.000 claims description 16
- 230000005684 electric field Effects 0.000 claims description 16
- 239000012491 analyte Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000009825 accumulation Methods 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 229930014626 natural product Natural products 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000003319 supportive effect Effects 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 abstract description 12
- 150000001413 amino acids Chemical class 0.000 abstract description 12
- 239000003792 electrolyte Substances 0.000 abstract description 12
- 239000007853 buffer solution Substances 0.000 abstract description 5
- 108020004414 DNA Proteins 0.000 description 43
- 235000014304 histidine Nutrition 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 11
- 241000894007 species Species 0.000 description 9
- 239000002253 acid Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 7
- 235000004279 alanine Nutrition 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000001488 sodium phosphate Substances 0.000 description 6
- 229960003339 sodium phosphate Drugs 0.000 description 6
- 229910000162 sodium phosphate Inorganic materials 0.000 description 6
- 235000011008 sodium phosphates Nutrition 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000008151 electrolyte solution Substances 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 4
- 150000001450 anions Chemical class 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 229940021013 electrolyte solution Drugs 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 239000006173 Good's buffer Substances 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 238000005251 capillar electrophoresis Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241001460678 Napo <wasp> Species 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108091036333 Rapid DNA Proteins 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 229920001222 biopolymer Polymers 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010013457 Dissociation Diseases 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 238000002479 acid--base titration Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- URSLCTBXQMKCFE-UHFFFAOYSA-N dihydrogenborate Chemical compound OB(O)[O-] URSLCTBXQMKCFE-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 208000018459 dissociative disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012145 high-salt buffer Substances 0.000 description 1
- 229960002163 hydrogen peroxide Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- 238000012358 sourcing Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N27/00—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means
- G01N27/26—Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electrochemical variables; by using electrolysis or electrophoresis
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L29/00—Semiconductor devices adapted for rectifying, amplifying, oscillating or switching, or capacitors or resistors with at least one potential-jump barrier or surface barrier, e.g. PN junction depletion layer or carrier concentration layer; Details of semiconductor bodies or of electrodes thereof ; Multistep manufacturing processes therefor
- H01L29/66—Types of semiconductor device ; Multistep manufacturing processes therefor
- H01L29/66007—Multistep manufacturing processes
- H01L29/66075—Multistep manufacturing processes of devices having semiconductor bodies comprising group 14 or group 13/15 materials
- H01L29/66227—Multistep manufacturing processes of devices having semiconductor bodies comprising group 14 or group 13/15 materials the devices being controllable only by the electric current supplied or the electric potential applied, to an electrode which does not carry the current to be rectified, amplified or switched, e.g. three-terminal devices
- H01L29/66409—Unipolar field-effect transistors
- H01L29/66477—Unipolar field-effect transistors with an insulated gate, i.e. MISFET
- H01L29/6656—Unipolar field-effect transistors with an insulated gate, i.e. MISFET using multiple spacer layers, e.g. multiple sidewall spacers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
Abstract
The following inventions relate to discoveries concerning the various parameters, electrolytes (buffers), and other conditions which improve or optimize the speed of DNA transport, the efficiency of DNA
hybridization reactions, and the overall hybridization specificity in microelectronic chips and devices. In particular, this invention relates to the discovery that low conductance zwitterionic buffer solutions, especially those containing the amino acid Histidine prepared at concentrations of ~50 mM and at or near the pI (isoelectric point ~pH 7.47), provide optimal conditions for both rapid electrophoretic DNA transport and efficient hybridization reactions. Hybridization efficiencies of at least a factor of 10 relative to the next best known buffer, Cysteine, are achieved. Test data demonstrate an approximately 50,000 fold increase in hybridization efficiency compared to Cysteine.
hybridization reactions, and the overall hybridization specificity in microelectronic chips and devices. In particular, this invention relates to the discovery that low conductance zwitterionic buffer solutions, especially those containing the amino acid Histidine prepared at concentrations of ~50 mM and at or near the pI (isoelectric point ~pH 7.47), provide optimal conditions for both rapid electrophoretic DNA transport and efficient hybridization reactions. Hybridization efficiencies of at least a factor of 10 relative to the next best known buffer, Cysteine, are achieved. Test data demonstrate an approximately 50,000 fold increase in hybridization efficiency compared to Cysteine.
Description
1015202530CA 02264780 2003-O5-O550338-141DESCRIPTIONMethods And Materials For OptimizationOf Electronic Hybridization ReactionsField of the InventionThis invention relates to buffers and electrolytesfor use in electronic devices adapted for medicaldiagnostic, biologicalgand other uses. More particularly,it relates to buffers and electrolytes for advantageoususe with DNA hybridizationanalysis carried outonmicroelectronic medical diagnostic devices.Background of the InventionRecently, there has been increasing interest indevices which combine microelectronics and molecularbiology. One such system is disclosed in "ACTIVEPROGRAMMABLE ELECTRONIC DEVICES FOR MOLECULAR BIOLOGICALANALYSIS AND DIAGNOSTICS", 08/146,504, filed1993, now issued- as United States Patent5,605,662. Thesystems disclosed therein will be referred to as APEXsystems.Serial No.November 1,No.AEEX systems are able to perform a wide varietyof functions which are advantageously used in molecularbiology reactions, such as nucleic acid hybridizations,antibody/antigen reactions, clinical diagnostics, andbiopolymer synthesis.APEX-type devices utilize buffers and electrolytesfor their operation. A buffer has been defined as achemical solution which is resistant to change in pH onthe addition of acid or alkali. See., e.g., Dictionary ofCoombs, Stocktonbuffers based onBiotechnology, Second Edition,As stated there,JamesPress. "traditionally,inorganic salts (phosphate, carbonate) and organic acidsalts (acetate, citrate, succinate, glycine,barbiturates, etc.) were used in biological experiments."maleate,101.520253 0CA 02264780 2004-02-0450338-142It is the object of this invention to discoverbuffers and electrolytes which are advantageously used inmolecular biology electronic devices which performreactions,hybridizations, diagnostics or synthesis.Summary of the InventionThe following inventions relate to our discoveriesconcerning the various parameters, electrolytes (buffers),and other conditions which improve or optimize the speed ofDNA transport, the efficiency of DNA hybridizationreactions, and the overall hybridization specificity in ourAPEX microelectronic chips and devices. In particular, thisinvention relates to the discovery that low conductancezwitterionic buffer solutions, especially those containingthe amino acid Histidine prepared at concentrations of10-100 mM, preferably about 50 mM, and at or near the pI(isoelectric point ~pH 7.47), provide optimal conditions forboth rapid DNA transport and efficient hybridizationreactions. Hybridization efficiencies of at least a factorof 10 relative to the next best known buffer, Cysteine, areachieved. Test data demonstrate an approximately 50,000fold increase in hybridization efficiency compared toCysteine.In one aspect the invention relates to a methodfor transporting and hybridizing target nucleic acids in amicroelectronic device having at least one test site bearinga capture nucleic acid, comprising the steps of:(1) applying a histidine buffer to the device, wherein thehistidine buffer has a low conductance of less than 1 mS,(2) applying current to the device to produce an electricfield at the test site, (3) transporting the target nucleicacids to the test site, and (4) hybridizing the targetnucleic acids to the capture nucleic acid at the test site1015202530CA 02264780 2004-02-0450338-142awith a hybridization efficiency which is at least a factorof 10 times greater than for cysteine buffer under the sameconditions.In another aspect the invention relates to amethod for enhancing the hybridization efficiency of targetnucleic acids in a microelectronic hybridization deviceincluding a microlocation test site having a capture nucleicacid, the microlocation adapted to be placed at least in afirst state wherein no electric field is generated and in asecond state wherein an electric field attractive to thetarget nucleic acids is generated at the microlocation,comprising the steps of: applying a histidine buffer to thedevice, providing target nucleic acid to the device, placingthe microlocation in the second state through application ofpower to the device to cause accumulation of the targetnucleic acids at a microlocation test site on the device,and hybridizing the target nucleic acids with the capturenucleic acid with an efficiency which is greater in thesecond state than in the first state.In another aspect the invention relates to amethod for electronically enhancing hybridization of DNAanalyte to single stranded capture DNA bound at a test sitein an electric field at a positively biased test site on amicroelectronic device, comprising the steps of: (1)applying a histidine buffer to the device, the buffer beingselected according to the following criteria: (a) thehistidine buffer having a low conductance of less than 1 ms,(pl)and (c) the histidine buffer having effective(b) the histidine buffer having an isoelectric pointabove 3.5,buffering capacity between pH 4 and pH 10, and (2) applyingcurrent to the test site on the microelectronic device in anamount sufficient to: (a) produce an electric field at thetest site on the microelectronic device, the test site being1.01.5CA 02264780 2004-02-0450338-14213positively biased relative to the DNA analyte, and (b)provide a net positive charge on the buffer molecules underinfluence of the electric field, the positively chargedbuffer molecules serving to stabilize DNA hybridizationbetween the DNA analyte and the single stranded capture DNAbound at the test site.Brief Description of the DrawingsFig. 1 is a plan view of a checkerboardarrangement utilizing a histidine buffer.Detailed Description of the InventionThere are various physical parameters which relateto the electrophoretic transport of DNA and other chargedanalytes in various types of electrolyte/buffer solutions.Certain of the devices, e.g., Applicant's APEX device asdescribed in United States Patent No. 5,605,662, referencedabove, are basically DC (direct current) electrical deviceswhich generate electric fields on the surface of the device.These fields,in turn, cause the101520253035W0 98/10273CA 02264780 1999-03-01PCT/U S97/ 144893electrophoretic transport of charged molecules to occur(+/-)By contrast the soâcalled Genosensorbetween oppositely biased. microlocations on thedevice surface.(impedance sensors), see, e.g., Hollis et al, "Optical andElectrical Methods and Apparatus for Molecular Detection",W093/22678, devices, see, e.g.,Washizu 25 Journal of Electrostatics, 109-123, 1990,An importantand dielectrophoresisinvolve the use of .AC electric fields.distinction related to these devices is that when these ACfields are applied, there is essentially no net currentflow in any of these systems, i.e, there is no electropho-retic propulsion for transport of the charged molecules.APEX type devices produce significant net direct current(DC) flow when a voltage is applied, which is recognizedas "the signature of electrophoresis". In electrophore-sis, the migration of ions or charged particles isproduced by electrical forces along the direction of theelectric field gradient, and the relationship of currentand voltage are important to this technology. Theelectrophoretic migration shows itself macroscopically asthe conduction of electric current in a solution under theinfluence of an applied voltage and follows Ohmâs law:V=RxIV is the electric potentialR is the electric resistance of the electrolyte [VxAâ1=R(§2)]I is the electric current [A].The resistance of the solution is the reciprocal ofthe conductance which can be measured by a conductometer.The conductance depends mainly on the ionic species of thebuffer/electrolytes and their concentration; thereforethese parameters are very important for electric fieldrelated molecular biology technology. The basiccurrent/voltage relationships are essentially the same forthe APEX technology assystem, although the electric fields produced are in trulyfor any other electrophoreticmicroscopic environments.101520253035W0 98/ 10273CA 02264780 1999-03-01PCT/U S97/ 144894APEXregarding the various ways of sourcing the current andThere are unique features of the systemvoltage, and how the current and voltage scenarios havebeen found to improve the performance of such systems. In(linear andparticular, various DC pulsing procedureslogarithmic gradients) appear to provide improvedhybridization stringency.Electrophoretic Transport Versus Ionic StrengthIt is well established in the field of electro-phoresis that there is a logarithmic decrease in themobility of the charged analyte species (proteins, DNA,etc.), which is inversely proportional to the square rootof the ionic strength of the electrolyte solution (seepage 83 and Fig. 3.16 in "Capillary Electrophoresis:Kuhn and S. Hoffstetter,At any given constant electricPrinciples and Practice", R.SpringerâVerlag, 1993).field strength, as the electrolyte concentration decreasesrelative to the analyte species (protein, DNA, etc.), theanalyte will be transported at a faster rate. Similarresults demonstrating this effect for a danyslated aminoacid have been shown by J.J. Issaq et. al.,Chromatographia Vol. 32, #3/4, August 1991, pages 155 to161 (see iJ1 particular Fig. 13 on page 157). Resultsdemonstrating this effect for DNA is different electrolytesolutions has been shown in P.D. Ross and R.L. Scruggs,pages 231 to 236, 1964 (see inparticular Fig. 1, page 232).Biopolymers Vol. 2,Ionic Strengthzconductance RelationshipFor those nonâbuffering electrolytes (sodiumchloride, potassium chloride, etc.) which involvecompletely dissociated anion and cation species insolution (Na* <-â-> Clâ, K* <-â-> Clâ, etc.), the ionicstrength and conductance are equivalent, i.e., theconductance will "usuallyâ be proportional to the ionicstrength. For those buffering electrolytes (phosphate,l01520253035W0 98/10273:strength or concentration.CA 02264780 1999-03-015which are in their2 Naâ <-ââ> PO4"2), the ionicstrength and conductance will usually be equivalent, i.e.,acetate, citrate, succinate, etc.)dissociated states (example:conductance is proportional to the ionic strength. For(MOPS , HEPES ,Ampholytes,those buffering electrolytes [Good BuffersTAPS ,etc.] which can have a zwitterionic species (no net chargeTricine, Bicine), Amino Acid Buffers,at their pI), the conductance will decrease by approxi-mately a factor of 10 for every pH unit difference betweenthe isoelectric point (pl) and the (pKa). For example, anamino acid in its zwitterionic state VOOCâCH(R)âNH{) willhave a conductance value which will be approximately 1000fold lower than when the "amino acid moiety" has a full(HOOC-CH(R)-NH2â <âââ> Xâ) ,negative charge (Y* <â-->' OOC-CH(R)âNH2). Thus,negative or positive charge develops on the amino acidnet positive charge or a fulla formalmoiety as it moves away from its pI, and the conductivityand ionic strength will begin to correlate. However, whenat or near the pI the conductance will be much lower thanis expected for that given ionic strength or concentra-tion. When used at or near their pI's, electrophoresistexts refer to the Good Buffers and amino acid buffers asat high(see page 88 of Capillary Electrophoresis:Kuhn and S. Hoffstetter,A commonly used electrophoresishaving "low conductances ionic strength orconcentration"Principles and Practice", R.Springer â Verlag, 1993).bufferconductivity than would be"Tris-Borate" actually has a significantly lowerexpected from_ its ionicThis may be due to the "triscation" "borate anion"and forming a relatively stablezwitterionic complex in solution. The conductivity of a100 mM TrisâBorate solution was determined to be 694us/cm, which is approximately 20 times lower than would beexpected from its ionic strength, and is roughly equiva-lent to a 5 mM sodium phosphate or sodium chloridesolution. Table i shows conductivity measurements of anumber of transport buffers.PCT/US97/14489101520253035CA02264780 1999-03-01PCT/US97/ 14489W0 98/10273Solution/B Average/Std.utter Measurement 1 Measurement 2 Measurement 3 Deviation10 mM 1.95 ms/cm 2.02 ms/cm 2.13 ms/cm 2.03+/-0.09Mgcl, ms/cm1 mM MgCl, 174 us/cm 208 us/cm 177 us/cm 186+/-18.8us/cm0.1 mM 16.9 us/cm 16.7 us/cm 18.3 us/cm 17.3+/-0.87Mgclz us/cm10 mM Nacl 1.07 ms/cm 1.10 ms/cm 1.18 ms/cm 1.12+/-0.057ms/cm1 mM NaC1 112 us/cm 115 us/cm 111 us/cm 112.7+/-2.08us/cm0.1 mM 8.80 us/cm 8.98 us/cm 10.5 us/cm 9.43+/-0.93NaCl us/cm20 mM 2.90 ms/cm 2.79 ms/cm 3.00 mS/cm 2.90+/-0.11NaPO. ms/cm10 mM 1.40 ms/cm 1.44 ms/cm 1.48 ms/cm 1.44+/-0.04NaP0, ms/cm1 mM Napo. 122 u.S/cm 128 us/cm 136 us/cm 12e.7+/-7.0us/cm50 mM TRIS 3.50 ms/cm 3.14 ms/cm 3.40 ms/cm 3.35-r/-0.19ms/cm10 mM TRIS 572 us/cm S62 us/cm 583 us/cm 572+/-10.5us/cm250 mM 141 us/cm 144 us/cm 15B MS/cm 147.6+/-9.07HEPES us/cm25 mM 9.16 us/cm 9.44 us/cm 10.5 us/cm 9.7+/-0.71HEPES us/cm3.3 mM 964 us/cm 964 us/cm 1.03 ms/cm 986+/-38.1Nacitrate us/cm5 mM 1.05 ms/cm 960 us/cm 1.01 ms/cm 1.01+/-0.045NaSucci- ms/cmnate5 mM 1.02 ms/cm 1.03 ms/cm 1.12 ms/cm 1.06+/-0.055Naoxalate ms/cm10 NM 901 #3/Cm 917 us/cm 983 [LS/cln 934+/-43.5NaAcetate us/cm250 mM 27.4 us/cm 17.3 us/cm 23.5 us/cm 22.7+/-5.09Cysteine us/cmMilli-Q <0.5 us/cm Detection limitwater of0.1 cell toolowTable 1l01520253035WO 98/10273CA 02264780 1999-03-01PCTIUS97l14489'7Zwitterionic Buffers/Conductance/Transport RateCertain advantages exist regarding the rate or speedtransport of DNA(Good buffers, amino acid buffers),or the Tris-Borate buffer at or near their pIs. These1) such buffers can be used at relatively highconcentrations to increase buffering capacity, 2)conductances are significantly lower than other types ofand 3)advantage of higher electrophoretic transport rates for(DNA).ofZwitterionic bufferselectrophoretic when usingare:theirbuffers at the same concentration, one gains thethe analyte of interestZwitterionic Buffer Capacity at the Isoelectric Point (nilAmino acid buffers do have buffer properties at theirpIâs. While a given amino acid may or may not have its"highest buffering capacity" at its pI, it will have somedegree of buffering capacity. Buffer capacity decreasesby a factor of 10 for every pH unit difference between thepI and the pKa; those amino acids with three ionizablegroups (histidine, cysteine, lysine, glutamic acid,aspartic acid, etc.) generally have higher bufferingcapacities at their pIâs than those amino acids with onlytwo dissociations (glycine, alanine, Forleucine, etc.).example, histidine p1 = 7.47, lysine pI=9.74, and glutamicacid pI=3.22, all have relatively good buffering capacityat their pIs, relative to alanine or glycine which haverelatively low buffering capacities at their pIs (see A.L.Lehninger, Biochemistry, 2ed, Worth Publishers, New York,1975; in particular Fig. 4-8 on page 79, and Fig. 4-9 onpage 80). Histidine has been proposed as a buffer for usein gel electrophoresis, see, e.g., U.S. Patent 4,936,963,but hybridization is not performed in such systems.Cysteine is in a more intermediate position, with regardthethe pKa for thesulfhydryl is 8.93, and the pKa for a amino group is10.78.to buffering capacity. The pI of cysteine is 5.02,pKa for the a carboxyl group is 1.71,An acid /base titration curve of 250 mM cysteine,WO 98/10273101520253035CA 02264780 1999-03-01PCT/US97ll44898shows that cysteine has a better "buffering capacity" atIn the pH 4 to 6range, the buffering capacity of cysteine is significantlybetter than 20 mM sodium phosphate,~ pH 5 than a 20 mM sodium phosphate.particularly at theHowever, in these pH ranges the conductance of~23 us/cm,compared to 20 mM sodium phosphate which has a value ofhigher pH.the 250 mM cysteine solution is very low~2.9 ms/cm, a factor of 100 times greater.theBuffers.Figure 1 showsConductivity Measurements of Various TransportSeveral electrophoretic techniques developed over 20years ago are based on the ability to separate proteins inzwitterionic buffers "at their pIs." These techniques arecalledElectrofocusingand"GelElectrophoresis of Proteins: A Practical Approach" Editedby B.D. Hames & D. Rickwood, IRL Press 1981).amino acid buffers and Good buffers were used for theseIsoelectrophoresis, Isotachophoresis,(see chapters 3 and 4 inVariousapplications, all at their pIâs (see Table 2, page 168 ofthe above reference).DNA Transport in Low Ionic Strength and Low ConductanceBuffersA series of fluorescent checkerboard experiments werecarried out using 2.5% agarose coated 5580 chips and theByTr-RCA5 fluorescent probe. â We were able to achievecheckerboard addressing in all of the(1) 250 mM HEPES(2) 10 pM sodium succinate, (3) 10 uM sodium citrate, and(4) distilled water.shown in Figure 1.rapid (6 second)following systems: (low conductance),The results for sodium citrate areWhile, some types of low conductanceor low ionic strength solutions may have somewhat bettercharacteristics, checkerboard addressing and rapid DNAtransport (6 to 12 second DNA accumulation on an 80 pmpad) were achieved âusing all of these systems.Additionally, DNA addressing APEX chips in distilled wateris possible because the DNA (itself a polyanion) is theWO 98/102731020253035CA 02264780 1999-03-01PCT/US97/ 144899electrolyte present in the bulk solution which providesthe conductance. Fig. 1 shows a plan view of an APEX chipusing histidine.Relationship of Electrophoretic Transport Rate and theCation[Anion SpeciesIn addition to the fact that the mobility of thecharged analyte species is relatedthemobility is also greatly influenced by the nature of the(DNA, proteins, etc.)to the ionic strength of the electrolyte solution,cation and anion species in the electrolyte solution (seepp 89 of "Capillary Electrophoresis:Thisdemonstrated for DNA transport in the above Biopolymers,Vol. 2, pp. 231-236, 1964 reference.of this reference shows the change in DNA mobility whenPrinciples andPractice" reference). particular point isFigure 1 on page 232using electrolytes with different univalent anions (Li * >Naâ>K*>TMA")different cations can have different association constantsat the same ionic strength. Basically,with the DNA phosphate groups, and/or change the hydrationspheres around the DNA molecules, which leads to a changein their transport rate.The instant invention relates to our discoveriesconcerning the various parameters, electrolytes (buffers),and other conditions which improve or optimize the speedof DNA. transport, the efficiencyâ of DNA. hybridizationreactions, and the overall hybridization specificity inelectric field molecular biology devices, especially APEXthisinvention relates to our discovery that low conductancemicroelectronic chips and devices. In particular,zwitterionic buffer solutions containing the amino acidHistidine prepared at concentrations of 10-100 mM,especially about 50 mM, at or near the pI (isoelectricpoint ~7.47), provide optimal conditions for both rapidelectrophoretic DNA transport and efficient hybridizationreactions. This advantage of the Histidine buffer isparticularly important for the APEX chip type devices.â_.............._..........- .... .s............,;.....,........................., . .W0 98/ 102731015CA 02264780 1999-03-01PCT/US97/ 1448910These particular devices (as opposed to the micromachinedtype devices) have limitations as to the amount of currentand voltages that can be applied. This limitation makesit difficult to achieve both rapid transport and efficienthybridization using the same buffer system. In thesecases, DNA transport was carried out in a low conductancebuffer limitedcurrent/voltage still produced rapid transport.(Cysteine or Alanine) where theUnderthese conditions the DNA accumulated at the test site, butdid not hybridize as efficiently. After transport inthese low conductance buffers, the solution was changed toa high salt buffer (> 100 mM sodium chloride or sodiumphosphate) which then produced an efficient hybridizationat the test site.Table 2 shows the results for a series of experimentswhich correlate the parameters of buffer capacity, pH, andthe conductivity, with DNA accumulation and hybridizationsensitivity (efficiency) using the APEX chip device.CA 02264780 1999-03-01WO 98110273 PCT/US97/1448911Relative Hybridiza-pH DNA SA- tionSolution Buffer Capacity at Conduc- Transport Biotin Sensitiv-pH 4-10 PI tivity Rate T12 ity of DNA(us) sensi-tivity[3-Alanine pK, - 3.6 + 7.3 10.0 +++++ 3 x 10âpK, - 10.2 (fastest)Taurine pK, - 1.5 +/- 4.6 4.5 ++++ > 7.5 xpx, - 3.7 10âCysteine pK, - 1.7 +/- 5.2 25.0 ++++ 3 x 107 7.5 x 10âpK2 - 8.3pK, - 10.85 Histidine px, - 1.8 +++ 7.6 212.0 +++ 3 x 10â 3 x 10âpx, - 6.0 (172.0pk, - 9.0 hipurity)Lysine pK, - 2.2 ++ 9.6 477.0 H» > 7.5 xpx, - 8.9 10â13K, - 10.3Napo, Complex + 7 . 41â 1, 400 . o +(slowest)TABLE 210152025In particular, Table 2 shows the effect of variouszwitterionic amino acid buffers [BâAlanine, Taurine,Cysteine, Histidine, Lysine, and Sodium Phosphate (not azwitterionic buffer)] on the hybridizability of thetransported target DNA to the specific capture DNA at thetest site. As to transport, the conductivity generallycorrelates with transport under the same field conditions.BâAlanine, Taurine and Cysteine show excellent transport,Histidine shows good transport, and Lysine and NaPO4 showfair transport. The DNA hybridization sensitivity is"normal DNA"polyanionic phosphate backbone.which has negatively chargedIn addition to theTable 2 also reports thereported forhybridization sensitivities,sensitivity for the streptavidin/biotin DNA probe captureaffinity.Table 2 the DNAtransport (accumulation) with low conductivity (BâAlanine,clearly shows correlation ofTaurine, Cysteine, Histidine). The table shows good_2L/20mM NaPO4 adjusted to pH 7.4.W0 98/ 10273101520253035CA 02264780 1999-03-01PCT/US97/ 1448912sensitivity for the streptavidin/biotin. probe affinityreaction using ï¬âAlanine, Cysteine, and Histidine. Asreflected in the sensitivity data in Table 2, Histidineprovides over four orders of magnitude betterhybridization efficiency then either Cysteine or othersuch as 20 mM NaPO,.Cysteine is at least a factor of 10,factor of 10%10â. Mosthybridization sensitivitythe Histidine buffer. Thus of allacid buffers presently tested, Histidine is the only oneand good DNA/DNAbuffers, The improvement relative tomore especially aand most especially at least a factor ofthat the DNAis very good forimportantly Table 2 shows(efficiency)the zwitterionic aminowhich provides both good transporthybridization efficiency.It is believed that the low conductivity of thebuffer the rapid DNA(accumulation). There are several possibleHistidine system accounts fortransportexplanations asrelatively efficient DNA/DNA hybridization.may be the good buffering capacity of Histidine.pI at 7.47, Histidine will buffer well under both acidicor basic conditions (see A.L.2ed, Worth Publishers,80). The APEX chip produceselectrode where the DNA is accumulated for hybridization,to why the Histidine buffer producesOne advantageWith itsLehninger, Biochemistry,l975,acid at the positiveNew York, Fig. 4-9 on pageand Histidine may effectively'buffer these conditions.More importantly, under these acidic conditions (pH<5) theprotonation of the imidazole group on the Histidine beginsto convert the molecule into a dicationic species. It maybe the case that this dicationic species with a positivelycharged a-amino group and a positively charge imidazolegroup may help to promote hybridization and stabilize theDNA/DNA hybrids formed at the positive electrode on theAPEX chip. dications, and polycations are knownto help DNA/DNA hybrids by therepulsion of the negatively charged phosphate backbones onthe doubleâstranded DNA structure.Cations,stabilize reducingIt is also possibleWO 981102731015CA 02264780 1999-03-01PCT/US97/1448913that the DNA/DNA/Histidine may also form some type ofstabilizing adduct from other electrochemical productsbeing produced at the positive electrode (hydrogenperoxide, etc.)While the instant embodiment utilizes naturallyoccurring Histidine, this invention is fully applicable toother natural or synthetic compounds which have good(or zwitterionicwhich allow DNAhybridization to be stabilized by charge stabilization orbuffering capacity, low conductivitycharacteristics) and have propertiesadduct formation.Although the foregoing invention has been describedin some detail by way of illustration and example forpurposes of clarity and understanding, it will be readilyapparent to those of ordinary skill in the art in light ofthe teachings of this invention that certain changes andmodifications may be made thereto without departing fromthe spirit or scope of the appended claims.
Claims (59)
1. A method for transporting and hybridizing target nucleic acids in a microelectronic device having at least one test site bearing a capture nucleic acid, comprising the steps of:
(1) applying a histidine buffer to the device, wherein the histidine buffer has a low conductance of less than 1 mS, (2) applying current to the device to produce an electric field at the test site, (3) transporting the target nucleic acids to the test site, and (4) hybridizing the target nucleic acids to the capture nucleic acid at the test site with a hybridization efficiency which is at least a factor of 10 times greater than for cysteine buffer under the same conditions.
(1) applying a histidine buffer to the device, wherein the histidine buffer has a low conductance of less than 1 mS, (2) applying current to the device to produce an electric field at the test site, (3) transporting the target nucleic acids to the test site, and (4) hybridizing the target nucleic acids to the capture nucleic acid at the test site with a hybridization efficiency which is at least a factor of 10 times greater than for cysteine buffer under the same conditions.
2. The method of claim 1 wherein the histidine buffer is selected according to the following criteria:
(a) the buffer having low conductance of less than 1 mS, (b) the buffer having an isoelectric point (pI) above 3.5, and (c) the buffer having effective buffering capacity between pH 4 and pH 10.
(a) the buffer having low conductance of less than 1 mS, (b) the buffer having an isoelectric point (pI) above 3.5, and (c) the buffer having effective buffering capacity between pH 4 and pH 10.
3. The method of claim 1 or 2, wherein the histidine buffer was prepared at a concentration of about 10-100 mM.
4. The method of any one of claims 1 to 3, wherein the histidine buffer having an isoelectric point was prepared at or about the isoelectric point.
5. The method of claim 4, wherein the isoelectric point is about 7.47.
6. The method of any one of claims 1 to 5, wherein the histidine buffer stabilizes hybridization between the target nucleic acids and the capture nucleic acid.
7. The method of any one of claims 1 to 6, wherein the histidine is a natural, zwitterionic compound.
8. The method of any one of claims 1 to 6, wherein the histidine is a synthetic, zwitterionic compound.
9. The method of any one of claims 1 to 8, wherein the histidine buffer has a low conductance of less than 500 µS.
10. The method of any one of claims 1 to 8, wherein the histidine buffer has a low conductance of less than 250 µS.
11. The method of any one of claims 1 to 8, wherein the histidine buffer has a low conductance of less than 100 µS.
12. The method of any one of claims 1 to 11, wherein the histidine buffer has a pI above 7.4.
13. The method of any one of claims 1 to 12, wherein the histidine buffer reduces repulsion between the capture nucleic acid and the target nucleic acids.
14. The method of any one of claims 1 to 13, wherein the histidine buffer reduces adduct formation between the capture nucleic acid and the target nucleic acids.
15. The method of any one of claims 1 to 14, wherein the hybridization efficiency is at least a factor of 100 times greater than for cysteine buffer under the same conditions.
16. The method of any one of claims 1 to 15, wherein the hybridization efficiency is at least a factor of 1,000 times greater than for cysteine buffer under the same conditions.
17. The method of any one of claims 1 to 16, wherein the hybridization efficiency is at least a factor of 50,000 times greater than for cysteine buffer under the same conditions.
18. A method for enhancing the hybridization efficiency of target nucleic acids in a microelectronic hybridization device including a microlocation test site having a capture nucleic acid, the microlocation adapted to be placed at least in a first state wherein no electric field is generated and in a second state wherein an electric field attractive to the target nucleic acids is generated at the microlocation, comprising the steps of:
applying a histidine buffer to the device, providing target nucleic acid to the device, placing the microlocation in the second state through application of power to the device to cause accumulation of the target nucleic acids at a microlocation test site on the device, and hybridizing the target nucleic acids with the capture nucleic acid with an efficiency which is greater in the second state than in the first state.
applying a histidine buffer to the device, providing target nucleic acid to the device, placing the microlocation in the second state through application of power to the device to cause accumulation of the target nucleic acids at a microlocation test site on the device, and hybridizing the target nucleic acids with the capture nucleic acid with an efficiency which is greater in the second state than in the first state.
19. The method of claim 18, wherein the histidine buffer has a low conductance of less than 1 mS.
20. The method of claim 18 or 19, wherein the histidine buffer was prepared at a concentration of about 10-100 mM.
21. The method of any one of claims 18 to 20, wherein the histidine buffer was prepared at or about the isoelectric point.
22. The method of claim 21, wherein the isoelectric point is about 7.47.
23. The method of any one of claims 18 to 22, wherein the histidine buffer stabilizes hybridization between the target nucleic acids and the capture nucleic acid in the second state.
24. The method of any one of claims 18 to 23, wherein the histidine is a natural compound with low conductance of less than 1 mS.
25. The method of any one of claims 18 to 23, wherein the histidine is a natural, zwitterionic compound.
26. The method of any one of claims 18 to 23, wherein the histidine is a synthetic compound with low conductance of less than 1 mS.
27. The method of any one of claims 18 to 23, wherein the histidine is a synthetic, zwitterionic compound.
28. The method of any one of claims 18 to 27, wherein the histidine buffer has a low conductance of less than 500 µS.
29. The method of any one of claims 18 to 27, wherein the histidine buffer has a low conductance of less than 250 µS.
30. The method of any one of claims 18 to 27, wherein the histidine buffer has a low conductance of less than 100 µS.
31. The method of any one of claims 18 to 30, wherein the histidine buffer has a pI above 7.4.
32. The method of any one of claims 18 to 31, wherein the hybridization efficiency is at least a factor of 100 times greater than for cysteine buffer under the same conditions.
33. The method of any one of claims 18 to 32, wherein the hybridization efficiency is at least a factor of 1,000 times greater than for cysteine buffer under the same conditions.
34. The method of any one of claims 18 to 33, wherein the hybridization efficiency is at least a factor of 50,000 times greater than for cysteine buffer under the same conditions.
35. The method of any one of claims 18 to 34, wherein the histidine buffer reduces repulsion between the capture nucleic acid and the target nucleic acids in the second state.
36. The method of any one of claims 18 to 35, wherein the histidine buffer reduces adduct formation between the capture nucleic acid and the target nucleic acids.
37. A method for electronically enhancing hybridization of DNA analyte to single stranded capture DNA
bound at a test site in an electric field at a positively biased test site on a microelectronic device, comprising the steps of:
(1) applying a histidine buffer to the device, the buffer being selected according to the following criteria:
(a) the histidine buffer having a low conductance of less than 1 mS, (b) the histidine buffer having an isoelectric point (pI) above 3.5, and (c) the histidine buffer having effective buffering capacity between pH 4 and pH 10, and (2) applying current to the test site on the microelectronic device in an amount sufficient to:
(a) produce an electric field at the test site on the microelectronic device, the test site being positively biased relative to the DNA analyte, and (b) provide a net positive charge on the buffer molecules under influence of the electric field, the positively charged buffer molecules serving to stabilize DNA
hybridization between the DNA analyte and the single stranded capture DNA bound at the test site.
bound at a test site in an electric field at a positively biased test site on a microelectronic device, comprising the steps of:
(1) applying a histidine buffer to the device, the buffer being selected according to the following criteria:
(a) the histidine buffer having a low conductance of less than 1 mS, (b) the histidine buffer having an isoelectric point (pI) above 3.5, and (c) the histidine buffer having effective buffering capacity between pH 4 and pH 10, and (2) applying current to the test site on the microelectronic device in an amount sufficient to:
(a) produce an electric field at the test site on the microelectronic device, the test site being positively biased relative to the DNA analyte, and (b) provide a net positive charge on the buffer molecules under influence of the electric field, the positively charged buffer molecules serving to stabilize DNA
hybridization between the DNA analyte and the single stranded capture DNA bound at the test site.
38. The method of claim 37, wherein the histidine buffer was prepared at a concentration of about 10-100 mM.
39. The method of claim 37 or 38, wherein the histidine buffer was prepared at or about the isoelectric point.
40. The method of claim 39, wherein the isoelectric point is about 7.47.
41. The method of any one of claims 37 to 40, wherein the histidine buffer stabilizes hybridization between the target nucleic acids and the capture nucleic acid.
42. The method of any one of claims 37 to 41, wherein the histidine buffer is a natural compound with low conductance.
43. The method of any one of claims 37 to 41, wherein the histidine buffer is a natural, zwitterionic compound.
44. The method of any one of claims 37 to 41, wherein the histidine buffer is a synthetic compound with low conductance.
45. The method of any one of claims 37 to 41, wherein the histidine buffer is a synthetic, zwitterionic compound.
46. The method of any one of claims 37 to 45, wherein the histidine buffer reduces repulsion between the capture nucleic acid and the target nucleic acids.
47. The method of any one of claims 37 to 46, wherein the histidine buffer reduces adduct formation between the capture nucleic acid and the target nucleic acids.
48. The method of any one of claims 37 to 47, wherein the histidine buffer has a low conductance of less than 500 µS.
49. The method of any one of claims 37 to 47, wherein the histidine buffer has a low conductance of less than 250 µS.
50. The method of any one of claims 37 to 47, wherein the histidine buffer has a low conductance of less than 100 µS.
51. The method of any one of claims 37 to 50, wherein the histidine buffer has a pI above 7.4.
52. The method of any one of claims 37 to 51, wherein the histidine buffer molecules provide protection to the analyte from the hydrogen generated at the positively biased test site by buffering the solution around the test site.
53. The method of claim 37, wherein the histidine buffer molecules having a net positive charge are cationic.
54. The method of claim 37, wherein the histidine buffer molecules having a net positive charge are dicationic.
55. The method of claim 37, wherein the histidine buffer molecules having a net positive charge are polycationic.
56. The method of any one of claims 37 to 55, wherein the histidine buffer is selected such that it is substantially incapable of shielding DNA and therefore not supportive of DNA hybridization in the absence of an electric field.
57. The method of any one of claims 1 to 16, wherein the hybridization efficiency is at least a factor of 25,000 times greater than for cysteine buffer under the same conditions.
58. The method of any one of claims 18 to 31, wherein the hybridization efficiency is at least a factor of 10 times greater than for cysteine buffer under the same conditions.
59. The method of any one of claims 18 to 33, wherein the hybridization efficiency is at least a factor of 25,000 times greater than for cysteine buffer under the same conditions.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70826296A | 1996-09-06 | 1996-09-06 | |
| US08/708,262 | 1996-09-06 | ||
| PCT/US1997/014489 WO1998010273A1 (en) | 1996-09-06 | 1997-08-18 | Methods and materials for optimization of electronic hybridization reactions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2264780A1 CA2264780A1 (en) | 1998-03-12 |
| CA2264780C true CA2264780C (en) | 2006-08-01 |
Family
ID=24845074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002264780A Expired - Fee Related CA2264780C (en) | 1996-09-06 | 1997-08-18 | Methods and materials for optimization of electronic hybridization reactions |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP1019711A4 (en) |
| JP (1) | JP4213216B2 (en) |
| KR (1) | KR100591626B1 (en) |
| CN (1) | CN1180248C (en) |
| AU (1) | AU723564B2 (en) |
| BR (1) | BR9712800A (en) |
| CA (1) | CA2264780C (en) |
| NZ (1) | NZ334314A (en) |
| WO (1) | WO1998010273A1 (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6051380A (en) * | 1993-11-01 | 2000-04-18 | Nanogen, Inc. | Methods and procedures for molecular biological analysis and diagnostics |
| US6468742B2 (en) | 1993-11-01 | 2002-10-22 | Nanogen, Inc. | Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip |
| US6379897B1 (en) | 2000-11-09 | 2002-04-30 | Nanogen, Inc. | Methods for gene expression monitoring on electronic microarrays |
| US5964995A (en) * | 1997-04-04 | 1999-10-12 | Caliper Technologies Corp. | Methods and systems for enhanced fluid transport |
| US6238909B1 (en) * | 1999-05-04 | 2001-05-29 | Motorola, Inc. | Method and apparatus for obtaining electric field-enhanced bioconjugation |
| AU783169B2 (en) * | 1999-09-27 | 2005-09-29 | Monsanto Technology Llc | Methods for determining oils in seeds |
| US7309581B2 (en) * | 2000-11-01 | 2007-12-18 | Sysmex Corporation | Method of staining, detection and counting bacteria, and a diluent for bacterial stain |
| GB0205455D0 (en) | 2002-03-07 | 2002-04-24 | Molecular Sensing Plc | Nucleic acid probes, their synthesis and use |
| US7153687B2 (en) | 2002-08-13 | 2006-12-26 | Hong Kong Dna Chips Limited | Apparatus and methods for detecting DNA in biological samples |
| JP4464664B2 (en) | 2003-06-13 | 2010-05-19 | 独立行政法人理化学研究所 | Biomolecule microarray substrate, biomolecule microarray, device and method for promoting interaction, and method for detecting interaction |
| US7314542B2 (en) * | 2004-09-23 | 2008-01-01 | Nanogen, Inc. | Methods and materials for optimization of electronic transportation and hybridization reactions |
| KR100785011B1 (en) * | 2006-04-07 | 2007-12-11 | 삼성전자주식회사 | Method for increasing the specificity of nucleic acid hybridization using zwitterionic compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4936963A (en) * | 1987-05-27 | 1990-06-26 | Abbott Laboratories | Polycationic buffers and method for gel electrophoresis of nucleic acids |
| US5188963A (en) * | 1989-11-17 | 1993-02-23 | Gene Tec Corporation | Device for processing biological specimens for analysis of nucleic acids |
| US6017696A (en) * | 1993-11-01 | 2000-01-25 | Nanogen, Inc. | Methods for electronic stringency control for molecular biological analysis and diagnostics |
| KR100314996B1 (en) * | 1994-11-10 | 2002-01-15 | 윌리암 제이. 버크 | Liquid distribution system |
| US5585069A (en) * | 1994-11-10 | 1996-12-17 | David Sarnoff Research Center, Inc. | Partitioned microelectronic and fluidic device array for clinical diagnostics and chemical synthesis |
-
1997
- 1997-08-18 CA CA002264780A patent/CA2264780C/en not_active Expired - Fee Related
- 1997-08-18 EP EP97938378A patent/EP1019711A4/en not_active Withdrawn
- 1997-08-18 KR KR1019997001868A patent/KR100591626B1/en not_active IP Right Cessation
- 1997-08-18 BR BR9712800-7A patent/BR9712800A/en unknown
- 1997-08-18 WO PCT/US1997/014489 patent/WO1998010273A1/en active IP Right Grant
- 1997-08-18 JP JP51267698A patent/JP4213216B2/en not_active Expired - Lifetime
- 1997-08-18 CN CNB97197960XA patent/CN1180248C/en not_active Expired - Fee Related
- 1997-08-18 NZ NZ334314A patent/NZ334314A/en unknown
- 1997-08-18 AU AU40719/97A patent/AU723564B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| KR20010029477A (en) | 2001-04-06 |
| CN1230255A (en) | 1999-09-29 |
| CN1180248C (en) | 2004-12-15 |
| EP1019711A1 (en) | 2000-07-19 |
| KR100591626B1 (en) | 2006-06-20 |
| AU723564B2 (en) | 2000-08-31 |
| WO1998010273A1 (en) | 1998-03-12 |
| AU4071997A (en) | 1998-03-26 |
| NZ334314A (en) | 2000-09-29 |
| JP2001501301A (en) | 2001-01-30 |
| EP1019711A4 (en) | 2001-06-13 |
| JP4213216B2 (en) | 2009-01-21 |
| CA2264780A1 (en) | 1998-03-12 |
| BR9712800A (en) | 1999-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2264780C (en) | Methods and materials for optimization of electronic hybridization reactions | |
| Hjertén et al. | Theoretical and experimental study of high-performance electrophoretic mobilization of isoelectrically focused protein zones | |
| CA2069053C (en) | Analysis of samples utilizing capillary electrophoresis | |
| Nelson et al. | On-line partial filling micelllar electrokinetic chromatography-electrospray ionization mass spectrometry | |
| US20080314751A1 (en) | Electrophoretic Separation of Analytes by Molecular Mass | |
| Arnett et al. | Investigation of the mechanism of pH‐mediated stacking of anions for the analysis of physiological samples by capillary electrophoresis | |
| WO1998010273A9 (en) | Methods and materials for optimization of electronic hybridization reactions | |
| Kartsova et al. | Preconcentration techniques in capillary electrophoresis | |
| US5176805A (en) | Reverse-polarity gel electrophoresis | |
| GB2264783A (en) | Electrophoretic analysis method utilising wave effect | |
| US7314542B2 (en) | Methods and materials for optimization of electronic transportation and hybridization reactions | |
| Richards et al. | An investigation of soluble ribonucleic acid by zone electrophoresis | |
| JPH10500489A (en) | Method for desalting biological samples to remove interfering substances in isoelectric focusing | |
| Yang et al. | Determination of chromium (VI) and lead (II) in drinking water by electrokinetic flow analysis system and graphite furnace atomic absorption spectrometry | |
| Gianazza et al. | Which electrodic solutions for immobilized pH gradients? | |
| JP4590615B2 (en) | Two-dimensional electrophoresis method | |
| Bhavsar et al. | A method to increase efficiency and minimize anomalous electrophoretic transfer in protein blotting | |
| Mirnik et al. | Electrophoretic Mobility and the Isoelectric Coagulation of the Silver Iodide Sols and Suspensions | |
| Garfin | Electrophoretic methods | |
| Cooper et al. | Electronic gel protein transfer and identification using matrix‐assisted laser desorption/ionization‐mass spectrometry | |
| Negro et al. | Cost‐effective media for the rapid and high resolution of small DNA fragments using polyacrylamide‐based electrophoresis | |
| Sidhorova et al. | Study of induced polarization of systems simulating soils during freezing | |
| Wagner et al. | Free Flow Electrophoresis for the separation and purification of biopolymers | |
| Rajput et al. | Western Blot: Theoretical Aspects | |
| RU2059233C1 (en) | Method of determining isopoint of polyelectrolytes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |